We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
- Authors
Webb, Mason J.; Sangsuwannukul, Thanich; van Vloten, Jacob; Evgin, Laura; Kendall, Benjamin; Tonne, Jason; Thompson, Jill; Metko, Muriel; Moore, Madelyn; Chiriboga Yerovi, Maria P.; Olin, Michael; Borgatti, Antonella; McNiven, Mark; Monga, Satdarshan P. S.; Borad, Mitesh J.; Melcher, Alan; Roberts, Lewis R.; Vile, Richard
- Abstract
Although patients benefit from immune checkpoint inhibition (ICI) therapy in a broad variety of tumors, resistance may arise from immune suppressive tumor microenvironments (TME), which is particularly true of hepatocellular carcinoma (HCC). Since oncolytic viruses (OV) can generate a highly immune-infiltrated, inflammatory TME, OVs could potentially restore ICI responsiveness via recruitment, priming, and activation of anti-tumor T cells. Here we find that on the contrary, an oncolytic vesicular stomatitis virus, expressing interferon-ß (VSV-IFNß), antagonizes the effect of anti-PD-L1 therapy in a partially anti-PD-L1-responsive model of HCC. Cytometry by Time of Flight shows that VSV-IFNß expands dominant anti-viral effector CD8 T cells with concomitant relative disappearance of anti-tumor T cell populations, which are the target of anti-PD-L1. However, by expressing a range of HCC tumor antigens within VSV, combination OV and anti-PD-L1 therapeutic benefit could be restored. Our data provide a cautionary message for the use of highly immunogenic viruses as tumor-specific immune-therapeutics by showing that dominant anti-viral T cell responses can inhibit sub-dominant anti-tumor T cell responses. However, through encoding tumor antigens within the virus, oncolytic virotherapy can generate anti-tumor T cell populations upon which immune checkpoint blockade can effectively work. Oncolytic viruses create an inflamed tumour microenvironment allowing T cells to respond to immune checkpoint blockade therapy more efficiently. Authors here show that in a hepatocellular carcinoma model, a dominant anti-viral rather than anti-tumour T cell response is elicited by an oncolytic vesicular stomatitis virus, unless the virus is designed to express tumour antigens, which restores therapeutic benefit.
- Subjects
T cells; TUMOR antigens; IMMUNE checkpoint inhibitors; ONCOLYTIC virotherapy; VESICULAR stomatitis; CELL populations; T cell receptors
- Publication
Nature Communications, 2024, Vol 15, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-024-49286-x